Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod + Pentavalent Antimony in Cutaneous Leishmaniasis
NCT00257530Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Dec 2005
- Primary completion
- Jun 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod in cutaneous leishmaniasis (CL), sponsored by Drugs for Neglected Diseases initiative. Started Dec 2005; status: completed.
02
Drugs
imiquimod
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT00257530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257530.